Online inquiry

IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4737MR)

This product GTTS-WQ4737MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL21 gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001207006.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 59067
UniProt ID Q9HBE4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4737MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6590MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ12360MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ2934MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ13408MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ12053MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ11163MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ6061MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ5162MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW